Please wait...

Rafi H(1), Kabbaj N, Salihoun M, Amrani L, Acharki M, Guedira M, Nya M, Amrani N.


Author information:

(1)EFD-Hepatogastroenterology Unit, Ibn Sina Hospital, UM5S, Rabat, Morocco.

BACKGROUND AND STUDY AIMS: Hepatic steatosis seems to be frequently found histopathologically in chronic hepatitis C virus (HCV)-infected patients. The aim of this study is to determine the influence of steatosis on HCV disease severity  (fibrosis) and to evaluate its impact on sustained virological response (SVR) to  antiviral therapy.

PATIENTS AND METHODS: From April 2008 to April 2010, 148 consecutive adults (87 females (59%) and 61 males (41%); mean age: 55.2 years) with HCV admitted for liver biopsy were included in this retrospective study. At least one element of metabolic syndrome was identified in all cases: Obesity (n=44), hyperlipidaemia (n=40), hypertension (n=29) and diabetes (n=21). Liver fibrosis was classified according to the Metavir score and hepatic steatosis described as following: S0:  absent; S1: minimal (<30%); S2: moderate (30-60%); and S3: severe (>60%). Patients were divided into two groups: S0S1 group (absent or minimal steatosis) and S2S3 group (moderate to severe steatosis). Of the 148 patients, 53 were treated with pegylated interferon and ribavirin combination therapy.

RESULTS: Steatosis was found in 40 patients (27%): S1 in 72.5%, S2 in 17.5% and S3 in 10% of cases. The distribution of patients according to the degree of fibrosis was as follows: in the S0S1 group, F1=12.4%, F2=36.5%, F3=21.1% and F4=21.1% and in the S2S3 group, F1=9%, F2=45.5%, F3=18.2% and F4=27.3%. There was no difference between the two groups regarding the degree of fibrosis (p≥0.80). The rate of SVR was 64%: 63% in the S0S1 group and 75% in the S2S3 group. The difference was not statistically significant (p=1).

CONCLUSION: Steatosis was found in 25% of cases. Liver steatosis in chronic hepatitis C is not a negative prognostic factor of response to combined antiviral therapy. These results must be confirmed by a large series of patients.

Copyright © 2011 Arab Journal of Gastroenterology. Published by Elsevier Ltd.

All rights reserved.


DOI: 10.1016/j.ajg.2011.07.003

PMID: 22055591  [Indexed for MEDLINE]


Arab J Gastroenterol. 2011 Sep;12(3):136-8. doi: 10.1016/j.ajg.2011.07.003. Epub  2011 Sep 15.

Achour J(1), Serraj I, Amrani L, Amrani N.

Author information:

(1)EFD-Hepato-Gastroenterology Unit, Ibn-Sina Hospital, UMV Souissi, Rabat, Morocco.

BACKGROUND: Intestinal tumors represent less than 6% of digestive tumors and, because of the limitations of intestinal investigations, these tumors are difficult to diagnose. In this context, capsule endoscopy (CE) has proven effective especially in patients with obscure digestive bleeding. The aim of the  present study was to calculate the frequency, and evaluate the diagnostic and therapeutic impact of CE in cases of small bowel tumors.

PATIENTS AND METHODS: A total of 95 patients (57 males and 38 females, mean age of 56 years) with negative endoscopy and colonoscopy results were directed to undergo CE examination.

RESULTS: Of the 95 patients, 13 (13.7%) were diagnosed with small bowel tumors. The main indications for CE were obscure (occult and overt) gastrointestinal bleeding. The mean duration of symptoms before diagnosis was 10 months. The final histological diagnosis was established through surgery. In our patients, this included gastrointestinal stromal tumor (nine cases), adenocarcinoma (two cases)  and carcinoid tumor (two cases).

CONCLUSION: This study revealed that the prevalence of intestinal tumors appears  to be higher than expected in patients through the use of CE.

Copyright © 2012. Published by Elsevier Masson SAS.

DOI: 10.1016/j.clinre.2011.10.005

PMID: 22579677  [Indexed for MEDLINE]

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):222-6. doi: 10.1016/j.clinre.2011.10.005. Epub 2012 May 11.

Atitar I(1), Amrani L, Serraj I, Amrani N.


Author information:

(1)EFD-HGE Unit, University Hospital Ibn Sina, UM5S, Rabat, Morocco.


DOI: 10.1016/j.clinre.2011.09.007

PMID: 22074642  [Indexed for MEDLINE]


Clin Res Hepatol Gastroenterol. 2012 Oct;36(5):399. doi: 10.1016/j.clinre.2011.09.007. Epub 2011 Nov 9.

Copyright by Digital Zone 2018. All rights reserved.